Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport - In Vitro and In Vivo Studies

Pharmaceutical Research

Volumn 32, Issue 5, 2015, Pages 1817-1829

  Lawless, Emma ^a   Griffin, Brendan T ^b   O'Mahony, Aoife ^b   O'Driscoll, Caitriona M ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

cyclosporine A; in vitro in vivo correlations; lipid formulations; lymphatic transport

Indexed keywords

CHLORPHENOTANE; CYCLOSPORIN; CYTOCHROME P450 3A INHIBITOR; ENZYME INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ANIMAL; CACO 2 CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; INTESTINE; INTESTINE ABSORPTION; LIPID METABOLISM; LYMPH; METABOLISM; RAT; SOLUBILITY;

ANIMALS; CACO-2 CELLS; CYCLOSPORINE; CYTOCHROME P-450 CYP3A INHIBITORS; DDT; ENZYME INHIBITORS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIPID METABOLISM; LYMPH; RATS; SAQUINAVIR; SOLUBILITY; TRIGLYCERIDES;

EID: 84930487568     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1578-x     Document Type: Article

References (38)

1. Porter CJH, Williams HD, Trevaskis NL. Recent advances in lipid-based formulation technology. Pharm Res. 2013;30(12):2971-5.
2. O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):617-24.
3. O'Reilly JR, Corrigan OI, O'Driscoll CM. The effect of mixed micellar systems, bile-salt fatty-acids, on the solubility and intestinal-absorption of clofazimine (B663) in the anaesthetized rat. Int J Pharm. 1994;109(2):147-54.
4. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15(5):405-15.
5. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-48.
6. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702-16.
7. Trevaskis NL, Charman WN, Porter CJH. Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? Mol Pharm. 2010;7(6):2297-309.
8. Griffin BT, O'Driscoll CM. An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat. Pharm Res. 2008;25(5):1125-33.
9. Charman WNA, Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34(1-2):175-8.
10. Myers RA, Stella VJ. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug - comparison to DDT and hexachlorobenzene. Int J Pharm. 1992;80(1):51-62.
11. Porter CJH, Charman SA, Charman WN. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J Pharm Sci. 1996;85(4):351-6.
12. Hauss DJ, Mehta SC, Radebaugh GW. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int J Pharm. 1994;108(2):85-93.
13. Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci. 2000;89(8):1073-84.
14. Faisal W, O'Driscoll CM, Griffin BT. Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport. J Pharm Pharmacol. 2010;62(3):323-31.
15. Nankervis R, Davis SS, Day NH, Shaw PN. Intestinal lymphatic transport of three retinoids in the rat after oral administration: Effect of lipophilicity and lipid vehicle. Int J Pharm. 1996;130(1):57-64.
16. Griffin BT, O'Driscoll CM. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J Pharm Pharmacol. 2006;58(7):917-25.
17. Seeballuck F, Ashford MB, O'Driscoll CM. The effects of Pluronic (R) block copolymers and Cremophor (R) EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003;20(7):1085-92.
18. Seeballuck F, Lawless E, Ashford MB, O'Driscoll CM. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res. 2004;21(12):2320-6.
19. Khoo SM, Edwards GA, Porter CJH, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90(10):1599-607.
20. Khoo SM, Prankerd RJ, Edwards GA, Porter CJH, Charman WN. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. J Pharm Sci. 2002;91(3):647-59.
21. Trevaskis NL, Caliph SM, Nguyen G, Tso P, Charman WN, Porter CJH. A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport. Pharm Res. 2013;30(12):3254-70.
22. Noguchi T, Charman WNA, Stella VJ. Lymphatic appearance of DDT in thoracic or mesenteric lymph duct cannulated rats. Int J Pharm. 1985;24(2-3):185-92.
23. Dahan A, Mendelman A, Amsili S, Ezov N, Hoffman A. The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: Comparison between anesthetized and freely moving conscious rat models. Eur J Pharm Sci. 2007;32(4-5):367-74.
24. Charman WNA, Stella VJ. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int J Pharm. 1986;33(1-3):165-72.
25. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26(5):394-404.
26. Holm R, Hoest J. Successful in silico predicting of intestinal lymphatic transfer. Int J Pharm. 2004;272(1-2):189-93.
27. O'Driscoll CM, Myers RA, Stella VJ. Blood and lymph transport of DDT after oral and parenteral administration to anesthetized rats. Int J Pharm. 1991;73(2):177-83.
28. Folch J, Lees M, Sloane-Stanley G. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226(1):497-509.
29. Gibney MJ, Connolly A. Uptake of exogenous and endogenous eicosapentaenoic acid by cultured human mononuclear cells. Br J Nutr. 1988;60(1):13-20.
30. Field FJ, Born E, Chen H, Murthy S, Mathur SN. Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: possible role of p-glycoprotein. J Lipid Res. 1995;36(7):1533-43.
31. Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev. 2004;56(9):1315-34.
32. Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24:381-8.
33. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2(9):807-18.
34. Ueda CT, Lemaire M, Gsell G, Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats. Biopharm Drug Dispos. 1983;4(2):113-24.
35. Takada K, Yoshimura H, Shibata N, Masuda Y, Yoshikawa H, Muranishi S, et al. Effect of administration route on the selective lymphatic delivery of cyclosporine A by lipid-surfactant mixed micelles. J Pharmacobio Dyn. 1986;9(2):156-60.
36. Wang TY, Liu M, Portincasa P, Wang DQH. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Investig. 2013;43(11):1203-23.
37. Ismailos G, Reppas C, Dressman JB, Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol. 1991;43(4):287-9.
38. Patton JS, Stone B, Papa C, Abramowitz R, Yalkowsky S. Solubility of fatty acids and other hydrophobic molecules in liquid trioleoylglycerol. J Lipid Res. 1984;25(2):189-97.